Desvenlafaxine Recommendations Report
Prof Dr Mazda Adli - Professor for Psychiatry and Chair of Fliedner Klinik, Centre for Psychiatry, Psychotherapy and Psychosomatic Medicine Charité-University Medicine, Berlin, Germany
Dr Antonio Lains - Director of Neuroscience and Mental Health Clinic, Hospital Cruz Vermelha, Lisbon, Portugal
Prof Dr Claudia Carmassi - Associate Professor of Psychiatry, Psychiatric Clinic, University of Pisa Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Article Information
Volume 9 Issue 2 December 2023, pages 50-57
Advisors
Dr Javier De Diego Adeliño -Psychiatrist, Hospital de la Santa Creu i Sant Pau and Associate Professor of Psychiatry of Universitat Autònoma de Barcelona, Barcelona, Spain
Prof Dr Mazda Adli – Professor for Psychiatry and Chair of Fliedner Klinik, Centre for Psychiatry, Psychotherapy and Psychosomatic Medicine Charité-University Medicine, Berlin, Germany
Dr Antonio Lains – Director of Neuroscience and Mental Health Clinic, Hospital Cruz Vermelha, Lisbon, Portugal
Prof Dr Claudia Carmassi – Associate Professor of Psychiatry, Psychiatric Clinic, University of Pisa Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Abstract:
Meeting objectives
• Obtain insights from an international panel of experts on the best way to position desvenlafaxine (DES) as an alternative for treating depression, which patient profiles can most benefit from its use, and other practical recommendations that may be useful for clinicians.
• Develop and circulate a report detailing key recommendations from the expert panel to guide the use of DES in clinical practice.
• Ultimately improve the quality of care for patients who need treatment with antidepressants.
Keywords:
Desvenlafaxine, Psychiatry, Desvenlafaxine Recommendations ReportFollow Us
Newsletter
Keep up to date with our latest
articles and journals
0 Comments